Summary
Cencora, Inc. (COR) reported solid financial performance for the quarter and six months ended March 31, 2011. Revenue saw modest growth driven by the AmerisourceBergen Drug Corporation (ABDC) segment, despite a decline in the AmerisourceBergen Specialty Group (ABSG) due to the discontinuation of a contract. Notably, gross profit and operating income showed significant increases, outperforming revenue growth, largely attributed to the successful launch and profitability of specialty generic products, particularly in oncology. The company is actively managing its capital resources, demonstrating strong cash flow from operations and maintaining substantial availability under its credit facilities. Cencora is also returning value to shareholders through share repurchases and consistent dividend payments. While facing some headwinds, such as the upcoming loss of a large retail customer and the ongoing investment in its ERP system implementation, the company projects continued revenue growth and expresses confidence in its liquidity and ability to meet its financial obligations.
Financial Highlights
56 data points| Revenue | $19.71B |
| Cost of Revenue | $19.03B |
| Gross Profit | $677.92M |
| SG&A Expenses | $291.04M |
| Operating Income | $361.63M |
| Net Income | $214.38M |
| EPS (Basic) | $0.78 |
| EPS (Diluted) | $0.77 |
| Shares Outstanding (Basic) | 274.32M |
| Shares Outstanding (Diluted) | 279.77M |
Key Highlights
- 1Revenue increased by 2.4% to $19.8 billion for the quarter and 2.6% to $39.6 billion for the six months ended March 31, 2011.
- 2Gross profit rose significantly by 12.3% for the quarter and 7.8% for the six months, with gross profit margin improving due to specialty generic launches and fee-for-service agreements.
- 3Operating income demonstrated strong growth, up 17.4% for the quarter and 11.9% for the six months, indicating improved operational efficiency despite higher operating expenses.
- 4Net income and diluted EPS showed robust year-over-year increases, with net income growing 18% for the quarter and 13% for the six months, and EPS up 22% and 17% respectively.
- 5The company maintained strong liquidity with significant availability under its revolving credit facilities and receivables securitization facility, totaling over $1.3 billion.
- 6Cencora actively repurchased shares, with $254.9 million in buybacks during the first six months of the fiscal year, and expects to complete its current $500 million repurchase program by year-end.
- 7The company is investing in its future with ongoing implementation of a new ERP system, which is contributing to increased operating expenses but is expected to enhance long-term efficiency.